We’re here to support you during this transition.
Bayer recently announced that Kogenate FS will be discontinued. We want patients and their caregivers to know that we are here to support you during this transition. Keeping the needs of patients and caregivers in mind, Bayer has carefully considered that you will need sufficient time to consider and make decisions about your next treatment. The timing of discontinuation will vary by Kogenate FS vial size. Customer demand may lead to depletion of the larger vial sizes during the fall of 2022. Remaining Kogenate FS vial sizes are anticipated to be available into 2023. It's important to work with your healthcare provider as you consider transitioning products.
Kovaltry and Jivi are available to meet the needs of patients currently taking Kogenate FS. Talk to your healthcare provider about which product might be right for you.
All adult and adolescent patients (12 and older) currently taking Kogenate FS who are interested in an extended half-life (EHL) product should talk to their healthcare provider about transitioning to Jivi.
For adults and adolescents ≥12Learn more
Hear from patients who have already transitioned from Kogenate FS to Kovaltry or Jivi.
Click here to hear patient stories.
Your Bayer Rep
Find your Bayer Rep, who can answer any questions you may have about the transition and steps you can take to find your next treatment.
Click here to locate the Bayer Rep nearest to you.
Most Kogenate FS patients who transition to Kovaltry or Jivi can receive either product at little to no out-of-pocket cost, through the Access Services by Bayer program.*†
Click here to learn more about our Patient Support options.
Call our dedicated Kogenate FS Hotline. Live helpline support is available 8:30 AM - 8:00 PM ET Monday-Friday.
Kovaltry and Jivi are covered for 99% of patients nationally‡§
*Co-pay program support is available for up to 1 year. Can include any out-of-pocket prescription costs, such as co-pay and co-insurance. Up to $20,000 in co-pay assistance available per year. Eligible patients will be auto-enrolled every January.
†Patients who are enrolled in any type of government insurance are not eligible. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.
‡Formulary status is believed to be accurate as of January 1, 2022 but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level. Lower co-pay costs do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status does not imply a comparison of efficacy, safety, or dosing.
§Jivi coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), Managed Medicaid (100%) & Medicare Advantage (100%). Percentage represents the coverage within the book of business. n=1,518, 51, 369, 748. Kovaltry coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), Managed Medicaid (100%) & Medicare Advantage (100%). Percentage represents the plan coverage within the book of business: n=1,798; 51; 410; 1,112.